Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney

What this Trial Is About

Researchers are studying whether analyzing DNA and protein materials found in urine can help detect urothelial cancer of the bladder and kidney. The study aims to understand if these analyses can predict how the cancer behaves in terms of remission and recurrence. This observational study includes patients with tumors and control patients without bladder cancer to evaluate the accuracy of new non-invasive testing methods compared to current standard procedures. Participants include two groups: one with bladder cancer patients scheduled for procedures like cystectomy, cystoscopy, or nephroureterectomy, and a control group without known bladder cancer. Urine samples will be collected through voiding and catheterization during scheduled procedures and follow-up visits over two years. The study will assess DNA mutations and protein biomarkers in urine, comparing these findings with standard cytology and cystoscopy results. Participants will provide urine samples at scheduled clinical visits and procedures, with samples processed for DNA and protein analysis. Researchers will use various molecular techniques to detect mutations and protein markers linked to bladder cancer presence and progression. The primary outcome is to evaluate the usefulness of these non-invasive urine tests in detecting bladder tumor cells. The study will continue collecting and analyzing samples until November 2028, with participants followed over two years for sample collection and monitoring.

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer